CONFIDENTIAL
04 · 2026
Head-and-neck Madelung's Disease’s action plan
A personalized synthesis of records, biomarkers, imaging, and literature, prepared for discussion with the client's physicians.
- Prepared for
- Sample · M.R., 52
- Condition
- MSL Type 1
- Pages
- 36
- Lead reviewers
- Giannini · Paramonov
- 01Executive summary
- 02Case synthesis
- 03Disease model — your version
- 04Specialist map — named surgeons and centers
- 05Clinical workup and imaging
- 06Signal analysis — your activation map
- 07Genetic findings — variant-level review
- 08DEXA body composition
- 09Intervention prioritization — Ternary Method applied
- 10Medical therapy — discussion points
- 11Supplement framework
- 12Lifestyle and alcohol protocol
- 13Physical therapy and lymphatic protocol
- 14Monitoring plan
- 1590-day execution blueprint
- 16Questions for your physicians
- 17Resources and communities
Executive summary
What this plan says and the four things that matter most in the next 90 days.
A 52-year-old male with Type 1 Madelung's Disease involving the posterior and lateral neck, one prior liposuction with recurrence, elevated triglycerides, low vitamin D and B12, and homozygous C282Y on HFE testing — a configuration that makes surgical re-planning, metabolic control, and iron management the three highest-leverage priorities.
- 01
- Reopen the surgical question. A staged open approach with a plastic reconstructive team is likely a better fit than repeat liposuction given the pattern of recurrence and the non-encapsulated tissue. Two expert opinions recommended in Section 4.
- 02
- Treat the HFE status as a meaningful finding. Homozygous C282Y with elevated ferritin warrants a hepatology referral and discussion of therapeutic phlebotomy — not a supplement decision.
- 03
- Alcohol: zero, monitored. Given the strength of the association, this is the single most important non-surgical step. A structured primary-care-supported cessation pathway is included.
- 04
- Screen for sleep apnea before any elective surgery. Neck-mass effect and male, middle-aged physiology make formal testing high-yield.
Case synthesis
Timeline, imaging, labs, and genetics reconstructed into one coherent picture.
Clinical timeline
| Year | Event |
|---|---|
| ~2010 | First noticed posterior-cervical fullness. Attributed to weight; not investigated. |
| 2013 | Neck mass now visible; consult with head & neck surgeon. Imaging consistent with diffuse lipomatous infiltration. |
| 2014 | First liposuction procedure. Good short-term cosmetic result. |
| 2016 | Integrative medicine consultation. Initial lifestyle plan, full B-complex, vitamin D, omega-3, red yeast rice, milk thistle. |
| 2017 | HFE genetic panel added. Homozygous C282Y identified. Ferritin and transferrin saturation elevated. |
| 2019 – present | Partial recurrence of neck fullness, primarily posterior. Intermittent alcohol use resumed for periods. |
Imaging summary
Most recent MRI of the neck (uploaded to intake) demonstrates non-encapsulated adipose tissue predominantly in the posterior and lateral cervical compartments, with modest submandibular involvement. No evidence of deep parapharyngeal extension. Anatomy is consistent with Type 1 (head and neck) multiple symmetric lipomatosis.
Laboratory profile (intake uploads)
| Marker | Value | Reference | Interpretation |
|---|---|---|---|
| Triglycerides | 284 mg/dL | < 150 | Elevated — expected in MSL; drives fenofibrate discussion. |
| LDL-C | 162 mg/dL | < 130 | Moderately elevated; context of MSL phenotype. |
| Vitamin B12 | 192 pg/mL | 200 – 900 | Low-normal; supplementation straightforward. |
| Vitamin D (25-OH) | 22 ng/mL | 30 – 80 | Deficient; dose to measured level. |
| Ferritin | 612 ng/mL | 30 – 300 | Elevated — with C282Y homozygosity, warrants hepatology. |
| Transferrin saturation | 58% | < 45% | Consistent with iron overload pattern. |
| ALT / AST | 46 / 38 U/L | < 40 / < 40 | Mildly elevated; hepatic imaging indicated. |
| A1c | 5.6% | < 5.7% | Upper end of normal; worth trending. |
| Uric acid | 7.1 mg/dL | < 7.0 | Borderline elevated. |
Genomic review (23andMe raw data)
Confirmed homozygous C282Y (HFE, rs1800562). H63D negative. No pathogenic mitochondrial variants identified at the coverage level of consumer genotyping; this does not rule out mtDNA causes of MSL, which cannot be reliably assessed from 23andMe data alone. Clinical-grade mitochondrial panel is a discussion point with a medical geneticist if progression continues despite surgery and lifestyle control.
Disease model — your version
Three overlapping drivers in this case — and what is actionable for each.
The pattern in this case fits the most commonly discussed modern model of Madelung's Disease: a mitochondrial signaling disorder in adipose tissue with a strong alcohol-related trigger and amplification by metabolic dysfunction. The additional HFE homozygosity introduces iron-loading as an independent, treatable stressor.
What that means practically
- Alcohol and iron overload are the two modifiable axes with the strongest leverage. Both have concrete interventions.
- Lipid control matters on its own, independent of any effect on the masses.
- Mitochondrial targeting with supplements is theory-based. Include as supportive, not as a primary lever.
See this depth applied to your condition.
This is a sample built on a composite case — we don’t publish the full sample. A Ternary Brief on your own situation is free and takes about three minutes.
You’re reading 3 of 17 sections. The full Precision Deep Dive continues with specialist map, clinical workup and imaging, signal analysis, genetic findings, and more.
Educational sample on a composite case. Your brief and any report are built from your own situation and are never shared.